Logo image of RVNC

REVANCE THERAPEUTICS INC (RVNC) Stock Fundamental Analysis

NASDAQ:RVNC - Nasdaq - US7613301099 - Common Stock - Currency: USD

3.65  +0.01 (+0.27%)

After market: 3.66 +0.01 (+0.27%)

Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to RVNC. RVNC was compared to 198 industry peers in the Pharmaceuticals industry. RVNC has a bad profitability rating. Also its financial health evaluation is rather negative. While showing a medium growth rate, RVNC is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

RVNC had negative earnings in the past year.
RVNC had a negative operating cash flow in the past year.
In the past 5 years RVNC always reported negative net income.
In the past 5 years RVNC always reported negative operating cash flow.
RVNC Yearly Net Income VS EBIT VS OCF VS FCFRVNC Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 -100M -200M -300M

1.2 Ratios

With a Return On Assets value of -39.96%, RVNC perfoms like the industry average, outperforming 44.62% of the companies in the same industry.
Industry RankSector Rank
ROA -39.96%
ROE N/A
ROIC N/A
ROA(3y)-60.64%
ROA(5y)-53.59%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
RVNC Yearly ROA, ROE, ROICRVNC Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -1K -2K

1.3 Margins

Looking at the Gross Margin, with a value of 72.61%, RVNC is in the better half of the industry, outperforming 79.57% of the companies in the same industry.
RVNC's Gross Margin has been stable in the last couple of years.
RVNC does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 72.61%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.51%
GM growth 5YN/A
RVNC Yearly Profit, Operating, Gross MarginsRVNC Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -10K -20K -30K -40K

More info and screens

2

2. Health

2.1 Basic Checks

RVNC does not have a ROIC to compare to the WACC, probably because it is not profitable.
RVNC has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, RVNC has more shares outstanding
RVNC has a worse debt/assets ratio than last year.
RVNC Yearly Shares OutstandingRVNC Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M
RVNC Yearly Total Debt VS Total AssetsRVNC Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 200M 400M 600M

2.2 Solvency

Based on the Altman-Z score of -6.34, we must say that RVNC is in the distress zone and has some risk of bankruptcy.
RVNC has a Altman-Z score of -6.34. This is in the lower half of the industry: RVNC underperforms 67.20% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -6.34
ROIC/WACCN/A
WACC8.5%
RVNC Yearly LT Debt VS Equity VS FCFRVNC Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 200M -200M 400M

2.3 Liquidity

RVNC has a Current Ratio of 4.12. This indicates that RVNC is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 4.12, RVNC is in line with its industry, outperforming 59.14% of the companies in the same industry.
A Quick Ratio of 3.05 indicates that RVNC has no problem at all paying its short term obligations.
RVNC has a Quick ratio of 3.05. This is comparable to the rest of the industry: RVNC outperforms 53.23% of its industry peers.
Industry RankSector Rank
Current Ratio 4.12
Quick Ratio 3.05
RVNC Yearly Current Assets VS Current LiabilitesRVNC Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 100M 200M 300M 400M

More info and screens

6

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 53.16% over the past year.
The Revenue has grown by 15.34% in the past year. This is quite good.
Measured over the past years, RVNC shows a very strong growth in Revenue. The Revenue has been growing by 129.20% on average per year.
EPS 1Y (TTM)53.16%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%77.3%
Revenue 1Y (TTM)15.34%
Revenue growth 3Y148.24%
Revenue growth 5Y129.2%
Sales Q2Q%5.47%

3.2 Future

RVNC is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 18.17% yearly.
RVNC is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 22.31% yearly.
EPS Next Y57.03%
EPS Next 2Y30.61%
EPS Next 3Y22.8%
EPS Next 5Y18.17%
Revenue Next Year12.8%
Revenue Next 2Y19.79%
Revenue Next 3Y22.43%
Revenue Next 5Y22.31%

3.3 Evolution

The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
RVNC Yearly Revenue VS EstimatesRVNC Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 200M 400M 600M 800M
RVNC Yearly EPS VS EstimatesRVNC Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 -2 -4

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for RVNC. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for RVNC. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
RVNC Price Earnings VS Forward Price EarningsRVNC Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
RVNC Per share dataRVNC EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2

4.3 Compensation for Growth

A more expensive valuation may be justified as RVNC's earnings are expected to grow with 22.80% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y30.61%
EPS Next 3Y22.8%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for RVNC!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

REVANCE THERAPEUTICS INC

NASDAQ:RVNC (2/5/2025, 8:25:21 PM)

After market: 3.66 +0.01 (+0.27%)

3.65

+0.01 (+0.27%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-07 2024-11-07/amc
Earnings (Next)03-04 2025-03-04/amc
Inst Owners72.87%
Inst Owner Change-0.97%
Ins Owners1.85%
Ins Owner Change-207.08%
Market Cap381.02M
Analysts70.67
Price Target5.25 (43.84%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)19.02%
Min EPS beat(2)4.62%
Max EPS beat(2)33.41%
EPS beat(4)4
Avg EPS beat(4)19.57%
Min EPS beat(4)4.62%
Max EPS beat(4)33.41%
EPS beat(8)5
Avg EPS beat(8)-1.49%
EPS beat(12)6
Avg EPS beat(12)-3.54%
EPS beat(16)10
Avg EPS beat(16)-1.96%
Revenue beat(2)0
Avg Revenue beat(2)-8.84%
Min Revenue beat(2)-14.73%
Max Revenue beat(2)-2.96%
Revenue beat(4)1
Avg Revenue beat(4)-4.4%
Min Revenue beat(4)-14.73%
Max Revenue beat(4)10.16%
Revenue beat(8)3
Avg Revenue beat(8)-2.2%
Revenue beat(12)6
Avg Revenue beat(12)-0.84%
Revenue beat(16)9
Avg Revenue beat(16)2.98%
PT rev (1m)-31.93%
PT rev (3m)-42.51%
EPS NQ rev (1m)-18.27%
EPS NQ rev (3m)-57.56%
EPS NY rev (1m)0%
EPS NY rev (3m)-13.24%
Revenue NQ rev (1m)6.51%
Revenue NQ rev (3m)-13.71%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-7.54%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1.54
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-1.93
EYN/A
EPS(NY)-1.11
Fwd EYN/A
FCF(TTM)-1.87
FCFYN/A
OCF(TTM)-1.83
OCFYN/A
SpS2.37
BVpS-1.56
TBVpS-1.63
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -39.96%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 72.61%
FCFM N/A
ROA(3y)-60.64%
ROA(5y)-53.59%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.51%
GM growth 5YN/A
F-Score3
Asset Turnover0.54
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 106.69%
Cap/Sales 1.63%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.12
Quick Ratio 3.05
Altman-Z -6.34
F-Score3
WACC8.5%
ROIC/WACCN/A
Cap/Depr(3y)40.78%
Cap/Depr(5y)54.97%
Cap/Sales(3y)6.23%
Cap/Sales(5y)171.26%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)53.16%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%77.3%
EPS Next Y57.03%
EPS Next 2Y30.61%
EPS Next 3Y22.8%
EPS Next 5Y18.17%
Revenue 1Y (TTM)15.34%
Revenue growth 3Y148.24%
Revenue growth 5Y129.2%
Sales Q2Q%5.47%
Revenue Next Year12.8%
Revenue Next 2Y19.79%
Revenue Next 3Y22.43%
Revenue Next 5Y22.31%
EBIT growth 1Y31.18%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year68.87%
EBIT Next 3Y26.12%
EBIT Next 5Y20.68%
FCF growth 1Y9.03%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y8.22%
OCF growth 3YN/A
OCF growth 5YN/A